Kalos Therapeutics, Inc., an emergent therapeutic company focused on treating the patient and not just a tumor with breakthrough technology which addresses the treatment of unmet and orphan medical needs in the areas of cancer and hyperproliferative diseases.
This unique chemostatic approach safely shrinks tumors and treats the related often fatal comorbidities, something no other company has done successfully. Kalos Therapeutics, Inc. a development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY.
The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
Michael Moffat, Cavendish co-founder and President explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of the Kalos Therapeutics, Inc. research and scientific insights in in the area of cell inhibition in cancer positions them to make a major contribution to the field of cancer therapeutics, treating patients in a non-toxic, manner and addressing comorbidities is an amazing innovation.”
“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to patient centric cytostatic cell inhibition in cancer and hyperproliferative diseases. Many virulent cancers are afflicting populations around the world today these patients are desperate for new therapies in cancers” said George Colberg, CEO and Co-Founder of Kalos Therapeutics, Inc. “We welcome the chance to interact with many of world’s leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.
About Cavendish Global:
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United S
About Kalos Therapeutics:
Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates primarily for the treatment of Cancer Age Related diseases and Animal Health. The ANP family of peptides has become the basis for a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases non-malignant hyperproliferative disorders and Animal Health.
Visit http://www.kalostherapeutics.com for more information.
Name: George Colberg
Organization: Kalos Therapeutics
Address: 4370 La Jolla Village Dr, Ste 400, San Diego, CA 92122